Information Provided By: 
Fly News Breaks for November 29, 2016
TXMD
Nov 29, 2016 | 14:09 EDT
Guggenheim analyst Louise Chen believes weakness in TherapeuticsMD is a compelling buying opportunity. Chen said the weakness appears to be driven by a short presentation which sounds like a "rehash" of a prior short thesis published on the blog site "SeekingAlpha.com" with little new information. The analyst expects positive data for TX-001HR in 4Q16, and potential approval for Yuvvexy on its PDUFA date of 5/7/17, both of which she believes have blockbuster potential. Chen has a Buy rating on TherapeuticsMD shares.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
